SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases ...

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biopharmaceutical company focused on developing treatments for rare diseases and cancer, has been making significant strides in its commercial and ...

Massachusetts Financial Services Co. MA lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 20.2% during the 3rd quarter, Holdings Channel reports. The firm ...

J.P. Morgan said its top biotech picks for 2025 were Vertex, Travere, SpringWorks, PTC Therapeutics, Wave Life Sciences, ...

Key stocks to watch include Tarsus Pharmaceuticals and SpringWorks Therapeutics, both showing strong potential based on ...

Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported phase 3 data at ESMO that sets up regulatory filings for its lead drug nirogacestat ...

A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases. SpringWorks is the brainchild of Lara Sullivan, a former Pfizer R&D strategy executive who gained Pfizer's ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) director Julie Hambleton has sold a total of $186,047 worth of company stock, according to a recent SEC filing. The transactions were ...